Determine the real-world incidence of acute gout prophylaxis (AGP) prescribing when a xanthine oxidase inhibitor (XOI) is initiated and describe characteristics of AGP prescribing.
Retrospective cohort analysis from 2007 to 2017 using medical and prescription claims from an administrative database (IQVIA™ Health Plan Claims Database) among adult patients with a diagnosis of gout. Primary endpoint was the proportion of patients receiving AGP among all patients newly initiated on XOI therapy. Secondary endpoints included incidence proportions of acute flare and of XOI discontinuation among patients who received AGP compared to those who did not. Chi-square and Fisher’s exact tests were used in univariate analysis of proportions between treatment groups.
A total of 7414 patients were included for analysis. There were 697 patients (9.4%) who received AGP with XOI initiation and colchicine alone was the most common medication used among patients who received prophylaxis (n = 303, 43.4%). The incidence proportion of patients with an acute gout flare within 3 months of index was 21.5% in the AGP cohort and 12.7% in the no prophylaxis cohort (p < 0.001). The proportion of patients who discontinued XOI within 12 months of initiation was 38.7% in the AGP cohort and 46.2% in the no prophylaxis cohort (p < 0.001).
In the real world, the proportion of patients who receive AGP with initiation of XOI therapy is low and discontinuation of XOI within 12 months of initiation is significant. In this analysis, use of AGP was not associated with a lower risk of acute gout flare after initiation of XOI therapy.
• Real-world acute gout prophylaxis (AGP) prescribing with xanthine oxidase inhibitor (XOI) initiation is very low despite current guideline recommendations
• More than one third of patients discontinue XOIs within 12 months of initiation regardless of AGP prescribing
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Availability of data and material
The authors confirm that the data supporting the findings of this study are available within the article.
Kuo CF, Grainge MJ, Zhang W, Doherty M (2015) Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 11(11):649–662. https://doi.org/10.1038/nrrheum.2015.91
Becker MA, MacDonald PH, Hunt BJ et al (2008) Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids 27(6):585–591. https://doi.org/10.1080/15257770802136032
Tilleman JA, Desimone EM II, McAuliffe R (2017) Urate-lowering therapy for prevention and treatment of gout flare. US Pharm 42(3):33–37
Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentão J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gòrska I, EULAR Standing Committee for International Clinical Studies Including Therapeutics (2006) EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65(10):1312–1324
Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R, American College of Rheumatology (2012) American College of Rheumatology guidelines for management of gout. Part II: therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 64(10):1447–1461. https://doi.org/10.1002/acr.21773
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76(1):29–42. https://doi.org/10.1136/annrheumdis-2016-209707
Qaseem A, Harris RP, Forciea MA, for the Clinical Guidelines Committee of the American College of Physician (2017) Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med 166(1):58–68. https://doi.org/10.7326/M16-0570
Sivera F, Andres M, Carmona L et al (2014) Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 73:328–335
Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, Hingorani A, Jaques R, Nuki G, British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG) (2007) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 46:1372–1374
Khanna PP, Fitzgerald J (2015) Evolution of management of gout: a comparison of recent guidelines. Curr Opin Rheumatol 27(2):139–146. https://doi.org/10.1097/BOR.0000000000000154
Harrold LR, Mazor KM, Negron A, Ogarek J, Firneno C, Yood RA (2013) Primary care providers’ knowledge, beliefs and treatment practices for gout: results of a physician questionnaire. Rheumatology (Oxford) 52:1623–1629. https://doi.org/10.1093/rheumatology/ket158
Wu EQ, Patel PA, Mody RR et al (2009) Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol 36(5):1032–1040. https://doi.org/10.3899/jrheum.080487
Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW (2006) Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 12(2):61–65
Saseen JJ, Agashivala N, Allen RR, Ghushchyan V, Yadao AM, Nair KV (2012) Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Rheumatology (Oxford) 51(11):2004–2012. https://doi.org/10.1093/rheumatology/kes183
Yu J, Qiu Q, Liang L, Yang X, Xu H (2018) Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real-world clinical setting. Mod Rheumatol 28(2):339–344. https://doi.org/10.1080/14397595.2017.1318467
Pal B, Foxall M, Dysart T, Carey F, Whittaker M (2000) How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol 19(1):21–25. https://doi.org/10.1007/s100670050005
Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA (2004) Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 31(12):2429–2432
Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS (2009) Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 11(2):R46. https://doi.org/10.1186/ar2659
Rashid N, Coburn BW, Wu Y et al (2015) Modifiable factors associated with allopurinol adherence outcomes among gout patients in an integrated health system. J Rheumatol 42(3):504–512. https://doi.org/10.3899/jrheum.140588
Mantarro S, Capogrosso-Sansone A, Tuccori M, Blandizzi C, Montagnani S, Convertino I, Antonioli L, Fornai M, Cricelli I, Pecchioli S, Cricelli C, Lapi F (2015) Allopurinol adherence among patients with gout: an Italian general practice database study. Int J Clin Pract 69(7):757–765. https://doi.org/10.1111/ijcp.12604
Scheepers LM, Burden AM, Arts IW et al (2018) Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). Rheumatology (Oxford) 57(9):1641–1650. https://doi.org/10.1093/rheumatology/key155
Rees F, Jenkins W, Doherty M (2013) Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 72:826–830. https://doi.org/10.1136/annrheumdis-2012-201676
Yamanaka H, Tamaki S, Ide Y, Kim H, Inoue K, Sugimoto M, Hidaka Y, Taniguchi A, Fujimori S, Yamamoto T (2018) Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre, randomised study. Ann Rheum Dis 77:270–276
The statements, findings, conclusions, views, and opinions contained and expressed in this publication are based in part on data obtained under license from IQVIA™. Source: IQVIA™ Health Plan Claims Data (formerly known as Legacy PharMetrics), January 1, 2007–September 30, 2017, IQVIA™. All Rights Reserved. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IQVIA™ or any of its affiliated or subsidiary entities.
The authors would like to thank R. Brett Mcqueen, PhD, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, who was involved in study design and review of results for this database analysis.
The study protocol was submitted to the Colorado Multiple Institutional Review Board (COMIRB) and was determined to be exempt.
The study protocol was submitted to the Colorado Multiple Institutional Review Board (COMIRB) and was determined to be exempt
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Marina L. Maes was a PGY2 resident at the University of Colorado at the time this research project was conducted.
About this article
Cite this article
Maes, M.L., Saseen, J.J., Wright, G. et al. Utilization of acute gout prophylaxis in the real world: a retrospective database cohort analysis. Clin Rheumatol 40, 1017–1026 (2021). https://doi.org/10.1007/s10067-020-05265-3